WCM Investment Management LLC Sells 15,423 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

WCM Investment Management LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 284,622 shares of the biopharmaceutical company's stock after selling 15,423 shares during the period. WCM Investment Management LLC owned 0.22% of Halozyme Therapeutics worth $13,659,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in HALO. Verdence Capital Advisors LLC lifted its stake in Halozyme Therapeutics by 1.9% in the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC lifted its stake in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Diversify Advisory Services LLC lifted its stake in Halozyme Therapeutics by 8.5% in the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company's stock worth $305,000 after purchasing an additional 418 shares during the last quarter. Sheaff Brock Investment Advisors LLC lifted its stake in Halozyme Therapeutics by 7.7% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company's stock worth $407,000 after purchasing an additional 507 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in Halozyme Therapeutics by 0.5% in the third quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company's stock worth $6,367,000 after purchasing an additional 561 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $60.89.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Up 0.9 %

NASDAQ:HALO traded up $0.50 on Thursday, hitting $58.61. The stock had a trading volume of 883,110 shares, compared to its average volume of 1,272,773. The company has a fifty day moving average price of $52.09 and a two-hundred day moving average price of $54.45. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $34.70 and a 1-year high of $65.53. The stock has a market cap of $7.46 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 0.44 and a beta of 1.25.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.